** Shares of  drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket

** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product

** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co

** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency

** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy

** Shares down over 99% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))